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Background
Multiple sclerosis (MS) is a primary cause of neurological disability in young adults and 
has been regarded as an autoimmune disease characterized by inflammatory demyelina-
tion, gliosis and axonal loss in the central nervous system (CNS) (Compston and Coles 
2008; Confavreux and Vukusic 2006). The etiology of MS has remained elusive to date; 
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however, the involvement of auto-reactive T and/or B cells has been suspected (Huseby 
et al. 2012; Pröbstel et al. 2015). Implication of immune cells in the pathophysiological 
processes of MS have been underpinned by the fact that immunosuppresive or immu-
nomodulatory therapies are effective in reducing the relapse number and in delaying 
the progression of relapsing remitting MS (Brinkmann 2009; Lim and Constantinescu 
2010). Among the drugs used for MS, FTY720, an agonist of sphingosine-1-phosphate 
(S1P) receptors, exhibits its efficacy by inhibiting the egress of naïve and central mem-
ory T and B cells from lymph nodes and probably through secondary beneficial effects 
on glia in the CNS via S1P receptors (Brinkmann 2009). Oral administration of FTY720 
resulted in a marked reduction in lymphocyte number (lymphopenia), in particular, in 
naïve and central memory T and B cells expressing chemokine receptor CCR7 being 
present in the secondary lymphoid organs and in peripheral blood. In contrast, effec-
tor/memory T cells without CCR7 expression showed a relative increase during FTY720 
therapy (Brinkmann 2009).
Recent studies have revealed that a subset of innate-like T cells called mucosal-asso-
ciated invariant T cells (MAITs) could play a role in the pathophysiology of MS. MAITs 
are characterized by their abundance in humans, occupying up to 10, 20, and 50 % of T 
cells in the intestinal lamina propria, in the peripheral blood, and in the liver, respec-
tively (Dusseaux et  al. 2011) (unpublished results). Contrary to conventional T cells, 
MAITs recognize vitamin B2 metabolites as antigens and promptly produce a pleth-
ora of cytokines and chemokines upon activation (Birkinshaw et  al. 2014; Le Bourhis 
et al. 2011; Wakao et al. 2013). MAITs are believed to play a pivotal role in host defense 
against bacterial and fungal infection as well as in human autoimmune diseases such 
as inflammatory bowel disease, systemic lupus erythematosus, psoriasis, and MS (Cho 
et al. 2014; Miyazaki et al. 2011; Serriari et al. 2014; Teunissen et al. 2014; Treiner and 
Liblau 2015). In the case of MS, MAITs have been found in lesions from postmortem 
brain samples, implying that MAITs are implicated in the pathophysiology of MS (Illés 
et al. 2004; Willing et al. 2014). However, there has been debate as to the frequency of 
MAITs in MS. While MAITs were reported to be decreased in peripheral blood from 
MS patients compared with those from healthy donors (HDs), Annibali and colleagues 
have shown that MAITs increased along with the disease duration (Miyazaki et al. 2011; 
Annibali et al. 2011; Willing et al. 2014).
In the present study, we analyzed how MS and relevant drugs affected the pheno-
type and functions of MAITs as well as those of conventional CD4 and CD8 T cells. 
Our study revealed that although the phenotypic features of MAITs were affected by the 
disease as well as by the drugs, MAITs, in particular, had the potential to produce the 
cytokines relevant to fighting bacterial infections and remained quasi-intact. Further-
more, the relative frequency of MAITs between HD and untreated MS patients did not 
differ but it increased upon FTY720 treatment in a time-dependent manner.
Methods
Patients
Venous blood samples were obtained from HDs and from relapsing-remitting MS 
patients presenting to Sapporo Neurology Clinics and Hokkaido University Hos-
pital, with informed consent (Table  1). The patients were either disease-modifying 
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treatment free (hereafter referred as untreated) (14 females and 3 males; mean age ± SD, 
38.4 ±  12.7  years), interferon (IFN) β1a- or b-treated (10 females and 3 males; mean 
age ± SD, 40.6 ± 8.6 years), or FTY720-treated (4 females and 3 males; mean age ± SD, 
34.1 ± 8.4 years). Among the patients who started on FTY720 therapy in 2012 at Hok-
kaido University Hospital, seven patients were, in general, followed before and at 3, 
12, 24 and 36 months after initiation of FTY720 (0.5 mg per day). MS was diagnosed 
based on the 2010 revised McDonald criteria for MS (Polman et al. 2011). The samples 
obtained from 16 HDs (13 females and 3 males; mean age ± SD, 38.5 ± 11.4 years) were 
used for phenotyping and functional assays, and those from 9 HDs (6 females and 3 
males; mean age ± SD, 30.9 ± 7.7 years) were used for absolute blood cell counting. For 
extensive analysis of MAITs, two untreated subjects were omitted due to the paucity of 
MAITs (less than 0.6 %). Therefore, samples from15 untreated were used for the further 
analysis. In the analysis evaluating the effects of FTY720 on MAIT cell frequency and on 
expression of the cell surface antigens, some samples were missing due to the unavail-
ability (see Additional file 1: Table S1).
FACS analysis
Peripheral blood mononuclear cells (PBMCs) from untreated, IFNβ-treated, FTY720-
treated subjects, and HDs were prepared using a Ficoll gradient and subjected to 8-color 
fluorescence-activated cell sorting (FACS) analysis, as described previously (Sugimoto 
et  al. 2015). Cell surface antigen expression was analyzed with the indicated phyco-
erythrin (PE)-labeled anti-human antibodies within Brilliant Violet 421-labeled CD3 
(UCHT1, Biolegend, Tokyo, Japan), allophycocyanin (APC)-labeled CD161 (HP-3G10, 
Biolegend), and fluorescein isothiocyanate (FITC)-labeled anti-Vα7.2 (3C10, Bioleg-
end). The reaction mixture also contained Brilliant Violet 605-labeled CD4 (RPA-T4, 
BD Biosciences), APC/Cy7-labeled CD8 (SK1, Biolegend), and PE/Cy7-labeled CD45RO 
(UCHL1, BD Biosciences, Tokyo, Japan). A complete list of PE-labeled cell surface anti-
gens used is found in Additional file 2: Table S2.
Intracellular cytokine assays were performed as follows. Cryopreserved PBMCs were 
thawed and treated with DNase, then incubated for 3 h at 37 °C in 5 % CO2 to restore the 
cells. Cells were then stimulated with phorbol 12-myristate 13-acetate (10 ng/ml) and 
ionomycin (1 μg/ml) (both from Wako Pure Chemicals, Osaka, Japan) in the presence 
of 5 µg/ml each of brefeldin A (Cell Signaling Technology, Tokyo, Japan) and monen-
sin (Wako Pure Chemicals) for 5 h at 37 °C in 5 % CO2. The cultured cells were stained 
Table 1 Subjects enrolled in this study
a Expanded Disability Status Scale
b NA not applicable
Criteria Number Sex (F:M) Age EDSSa
Median Mean ± SD Median Mean ± SD
HD 16 13:3 36 38.4 ± 11.4 NAb NA
Untreated (UT) 17 14:3 38 38.4 ± 12.7 1.5 1.9 ± 1.7
Follow-up after FTY treatment 7 4:3 37 34.1 ± 8.4 2 1.9 ± 1.5
IFNβ treated 12 9:3 41 41.9 ± 8.4 2 2.0 ± 1.0
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with antibodies against PerCP/Cy5.5-TCR Vα7.2 (3C10, Biolegend), PE-Cy7-CD3 (SK7, 
BD Biosciences), PE-CF594-CD4 (RPA-T4, BD Biosciences), APC/H7-CD8 (SK-1, BD 
Biosciences), and Brilliant Violet 421-CD161 (HP-3G10, Biolegend) and permeabilized 
with BD Cytofix/Cytoperm solution (BD Biosciences) according to the manufacturer’s 
instructions. Intracellular cytokines were stained with antibodies against Alexa Fluor 
488-IFNγ (B27, BD Biosciences), PE-tumor necrosis factor (TNF) α (Mab11, Biolegend), 
Alexa Fluor 647-granulocyte/macrophage-colony stimulating factor (GM-CSF) (BVD2-
21C11, BD Biosciences), and Brilliant Violet 510-IL-17A (N49-653, BD Biosciences). 
Stained cells were acquired using a BD ARIA II (BD Biosciences) and analyzed using 
FlowJo version 9.9 (FlowJo, LLC) and SPICE version 5.35 (http://exon.niaid.nih.gov/
spice, National Institute of Allergy & Infectious Diseases, NIH) (Roederer et al. 2011).
Absolute cell counting
EDTA-anticoagulated whole blood was stained with antibodies against FITC-CD45, 
Brilliant Violet 421-CD3, Brilliant Violet-CD4, APC/H7-CD8, APC-CD161, and PerCP/
Cy5.5-TCR Vα7.2, and lysed using 1X BD FACS lysing solution (BD Biosciences). Abso-
lute cell numbers in each cell population were analyzed using a MACSQuant analyzer 
(Miltenyi Biotec) with volumetric acquisition.
Statistics
Statistical analyses of FACS data were performed using GraphPad Prism (ver. 6). The sig-
nificance of differences in the expression of cell surface antigens was evaluated using the 
Mann–Whitney U test or Kruskal–Wallis H test with Dunn’s multiple comparison test. 
P values <0.05 were considered to indicate statistical significance. Change in the rela-
tive frequency of MAITs upon FTY720 treatment was evaluated with Friedman’s test. 
Two-way AVONA was used for evaluating the difference among HDs, untreated- and 
FTY720-treated subjects in terms of the cytokine production profile from MAITs, CD4 
T cells, and CD8 T cells and P values were corrected with Holm-Sidak test.
For the cytokine production profiling analysis, partial permutation test has been 
employed with SPICE for the pie chart (Roederer et al. 2011).
Results
Relative frequency of MAITs in MS
MAITs are mainly composed of CD8 cells or double negative cells harboring nei-
ther CD8 nor CD4, and of few CD4 cells (Le Bourhis et al. 2011). To assess a possible 
implication of MAITs in MS, MAITs (Vα7.2+CD161hi) were analyzed for their expres-
sion of CD8 and CD4. We first examined the effects of the disease and of the drugs for 
MS on these subsets. While there was no or little difference in the relative frequency of 
MAITs between HD and untreated subjects, CD8hi MAITs were significantly decreased 
in untreated subjects compared with those in HDs, resulting in more CD8lo/neg MAITs 
(hereafter referred as double negative (DN) MAITs) in MS (Fig. 1a, b). Such depletion of 
CD8hi cells was also observed in IFNβ- and FTY720-treated subjects (data not shown, 
and Fig. 1a). In marked contrast, no such change was observed in conventional CD8 T 
cells irrespective of the disease and the drug treatment (data not shown). Although there 
was no significant difference in the frequency of conventional CD4 and CD8 T cells 
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between HD and untreated subjects, and between untreated and IFNβ-treated subjects, 
FTY720 induced a decline in the frequency of CD4 T cells concomitant with an increase 
in CD8 T cells compared with that in untreated subjects (Additional file 3: Figure S1). 
Then, we assessed the relative frequency of total MAITs (Vα7.2+CD161hi cells) in T cells 
(CD3+ cells), and of CD8hi MAITs, DN MAITs, and CD4 MAITs relative to total MAITs 
between untreated and IFNβ-treated subjects. The relative frequency of MAITs did not 
differ between the groups (Fig. 1c). Furthermore, IFNβ had little effect on the frequency 
of DN, CD8hi, and CD4 MAITs (Fig.  1c). We longitudinally examined the effects of 
FTY720 on the frequency of MAITs. FTY720 treatment for 3 months (FTY-3 m), 1 year 
(FTY-1y) and 2 years (FTY-2y) significantly enhanced the relative frequency of MAITs 
compared with that in the pre-treatment state (Fig.  2, total). Although some patients 
continued to increase the frequency after 1 year, others started to show a decline (Fig. 2, 
total). While there was no significant difference in the frequency of DN MAITs between 
untreated and FTY-3 m groups, it declined in subjects treated for 3 years (FTY-3y) com-
pared with that in FTY-1y and -2y (Fig. 2, DN). Of note was that after 3 years’ treatment, 
















































































































































































Fig. 1 CD8 MAITs consist of CD8hi and CD8hi/lo (DN) MAITs cells. a A representative FACS profile of 
mucosal-associated invariant T cells (MAITs) from a healthy donor (HD), a disease-modifying treatment free 
(untreated:UT) subject, and an FTY720-treated MS subject (MS/FTY720). MAITs are identified as cells harbor-
ing Vα7.2 and CD161 in CD3+ T cells. Vα7.2+ CD161hi cells were gated, and the expression levels of CD4 and 
CD8 were analyzed. The number in the figure shows the percentage of the indicated populations. b Differ-
ence in the relative frequency of MAIT cell subsets between HDs and untreated subjects. Relative frequency 
of total MAITs (Vα7.2+ CD161hi cells in the total CD3+ cells) from HDs (n = 10) and that from untreated 
subjects (UT, n = 15) are plotted (total). Relative frequency of DN MAITs, CD8hi MAITs, and CD4 MAITs in 
total MAITs are plotted (DN, CD8hi, and CD4, respectively). c The effect of INFβ on the frequency of MAITs. 
Relative frequency of total MAITs and that of the MAIT cell subset in total MAITs from UT (n = 15) and from 
INFβ-treated subjects (n = 12) are plotted (total, DN, CD8hi, and CD4, respectively). b, c All data are presented 
as horizontal lines: median; boxes: 25th percentile and 75th percentile; whiskers: minimum and maximum. P 
values after Mann–Whitney U test are shown
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40.2 vs. 33.9  %, Figs.  1b, 2). The same regimen also resulted in the recovery of CD8hi 
MAITs to a degree observed in HDs (median; 59.1 vs. 61.1  %, Figs.  1b, 2). Although 
FTY-3 m resulted in a significant decrease in the frequency of CD4 MAITs relative to 
untreated subjects, 3 years’ intake did not restore their frequency as observed in CD8hi 
MAITs (Figs. 1b, 2).
DN MAITs are characteristic in MS
Having established that most MAITs have decreased CD8 expression in untreated and 
FTY720-treated subjects compared with that in HDs, we next addressed whether DN 
MAITs harbored a different profile of cell surface antigen expression using HD PBMCs. 
Analysis with an array of antigens (Additional file  2: Table S2) has uncovered that co-
stimulatory molecules CD27, CD28, and CD278 (ICOS), and an integrin family mem-
ber, CD49d, exhibited decreased expression in these cells relative to that in CD8hi MAITs, 
whereas expression of a multi-drug efflux pump, CD243, showed the opposite phenotype 
(Table 2 and Additional file 4: Figure S2A). On the contrary, there was no difference in 
expression of CCR5, CCR6, a memory marker CD45RO, CD95, CD218a [IL-18 receptor 
















































































Fig. 2 Effects of FTY720 on MAITs. Upper panel The frequency of MAITs post FTY720 treatment. The frequency 
of MAITs (Vα7.2+ CD161hi cells) relative to total T cells (CD3+ cells) in the blood from subjects before (UT(pre)) 
and after FTY720-treatment (3 months, 1, 2 and 3 years; n = 7) is shown. Each individual was followed up to 
3 years. The data are analyzed with Friedman test (from UT (Pre) to 2 years) with Dunn’s multiple comparison 
test for all the possible combinations. Groups showing a difference are indicated with an asterisk (*P < 0.05; 
**P < 0.01). Lower panel: The effect of FTY720 on the subset frequency of MAITs. The percentage of DN, CD8hi, 
and CD4 MAITs relative to total MAITs in blood from untreated subjects (UT, n = 15) and FTY720-treated 
(n = 7) subjects are shown. 3 months, 1, 2, and 3 years; subjects received FTY720 for 3 months, 1, 2, and 
3 years, respectively. Data are analyzed with Kruskal–Wallis test with Dunn’s multiple comparison test for all 
the possible combinations. Groups showing a difference are indicated with an asterisk (*P < 0.05; **P < 0.01). 
All data are presented as horizontal lines: median; boxes: 25th percentile and 75th percentile; whiskers: mini-
mum and maximum
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α (IL-18Rα)], and CD127 [IL-7 receptor α (IL-7Rα)] between CD8hi MAITs and DN 
MAITs (Additional file 4: Figure S2B). Comparison among the different subsets of MAITs 
also revealed differences in expression. The expression of CCR4, CD95, and ICOS in 
CD4 MAITs showed an increase compared with that in CD8hi MAITs and in DN MAITs 
(Table 2 and Additional file 4: Figure S2C). Conversely, the expression of an inflammatory 
chemokine receptor, CCR5, a dipeptidase responsible for processing several chemokines 
and cytokines, CD26, and a signaling lymphocyte associated molecule (SLAM) family 
member, CD244 declined in CD4 MAITs relative to that in CD8hi MAITs and DN MAITs 
(Table 2 and Additional file 4: Figure S2C). Furthermore, CD27 and CD49d expression in 
CD8hi MAITs was higher than that in DN MAITs (Table 2 and Additional file 4: Figure 
S2C). The expression level of CD127 (IL-7Rα) and CD279 (PD1) in CD4 MAITs increased 
relative to that in DN MAITs (Table 2 and Additional file 4: Figure S2C), whereas there 
was no difference in the expression of CCR6, CD28, CD45RA, CD107a, CD150, CD218a 
(IL-18Rα), NKG2D, and CD45RO (Additional file 4: Figure S2D).
Profile of cell surface antigens in MAITs reflected the disease status
We extended our study to examine whether there were any markers in MAITs that 
could distinguish diseases states using an array of antigens (Additional file 2: Table S2). 
The expression of CCR5, CCR6, CD95, CD127, and CD150, increased in untreated sub-
jects compared with that in HDs in both CD8hi and DN MAITs ( Table  3 and Addi-
tional file 5: Figure S3A). Similarly, CD45RO decreased in untreated subjects compared 
with that in HDs in both CD8hi and DN MAITs (Table  3 and Additional file  5: Fig-
ure S3A). We then analyzed the effects of the drugs for MS on the expression of these 





CCR4 – – +
CCR5 ++ ++ +
CCR6 + + +
CD26 ++ ++ ++
CD27 + + +
CD28 ++ ++ ++
CD45RA + + +
CD49d + ++ +
CD95 + + ++
CD107a + + –
CD127 + ++ ++
CD150 + + +
CD244 + ++ –
CD279 – + +
ICOS + + +
IL18Rα + + +
NKG2D + + –
CD45RO ++ ++ ++
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markers. IFNβ treatment resulted in a decrease in the expression of CCR6 and CD49d 
relative to that in untreated subjects, whereas the expression of ICOS was augmented 
in both CD8hi and DN MAITs (Table 3 and Additional file 5: Figure S3B). Of note, a NK 
receptor, NKG2D, showed a decline only in DN MAITs. In CD8hi MAITs, a decline of 
CD28 and CD127 expression was observed, whereas level of a degranulation marker, 
CD107a, and CD279 (PD-1) increased (Table 3 and Additional file 5: Figure S3B). We 
then assessed the effects of FTY720 on expression of the cell surface antigen in DN 
MAITs and CD8hi MAITs. FTY-1y resulted in a decrease in the expression of CD49d 
and CD127 compared with those in untreated subjects in both CD8hi and DN MAITs 
(Fig. 3). Of note, the same regimen led to a decline in CD27 expression concomitant 
with an increase in CD107a in DN MAITs, as observed in the terminal differentiation 
of effector cells (Fig. 3) (Brenchley et al. 2003). While FTY-2y resulted in an increase 
in CCR5 expression in CD8hi MAITs compared with FTY-1y, FTY720 did not affect 
the expression of CD26, CD28, CD45RA, CD69, CD150, and CD243 in MAITs (Addi-
tional file  6: Figure S4A). Intriguingly, FTY-2y resulted in a decline in the expression 
of CD45RO in DN MAITs concomitant with an increase in CD45RA in both DN and 
CD8hi MAITs compared with that in HDs (Additional file 6: Figure S4B). 
Lymphocytes decreased during FTY720 treatment
We next addressed whether FTY 720 therapy led to a decrease in lymphocytes in the 
peripheral blood. Just 10–30  days post treatment, the absolute lymphocyte counts 
declined to 15–20 % of the pre-drug state in 5 patients. The absolute lymphocyte counts 
in each individual were kept relatively constant throughout drug treatment periods up 
to 3.5 years (Fig. 4a). We then measured the absolute lymphocyte number in patients 
Table 3 Changes in  the cell surface antigen expression between  HD and  UT, and  UT 
and IFNβ-treated subjects
a log 10median MFI for HD
median MFI for UT
b log 10 median MFI for UT
median MFI for IFNβ
c Statistical significances are shown with asterisks (*P < 0.05; **P < 0.01; ***P < 0.001) and ns not significant
Markers HD vs. UT UT vs. IFNβ

















CCR5 0.29 **** 0.27 *** −0.08 ns −0.05 ns
CCR6 0.55 *** 0.73 *** −0.44 **** −0.34 ***
CD28 0.05 ns 0.14 * 0.02 ns −0.05 *
CD45RO −0.39 ** −0.45 ** −0.09 ns 0.02 ns
CD49d 0.06 ns 0.00 ns −0.10 * −0.13 *
CD95 0.18 *** 0.27 *** 0.02 ns 0.00 ns
CD107a 0.10 ns 0.04 ns −0.01 ns 0.16 *
CD127 0.20 ** 0.09 * 0.00 ns −0.09 *
CD150 0.33 ** 0.27 * −0.10 ns 0.02 ns
CD279 nd – 0.00 ns nd – 0.22 **
ICOS 0.09 ns 0.06 ns 0.12 * 0.06 *
NKG2D 0.05 ns 0.04 ns −0.32 * −0.20 ns
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treated with FTY720 for 3 years. Although the relative frequency of MAITs was twice 
that in HDs, the absolute number declined to one-sixth of that in HDs (data not shown 
and Fig. 4b). Similarly, CD8 T cell numbers represented 18.6 % of that in HDs, whereas 
CD4 T cell numbers were one-thirtieth of that in HDs (Fig.  4b). Notably, regardless 
of the fact that T cell (CD3+ cells) numbers declined to one-eleventh of that in HDs, 
the total lymphocyte number decreased to one-fifth of that in HDs. Surprisingly, white 
blood cell (CD45+ cells) numbers diminished only to two-thirds of that in HDs, indicat-
ing that FTY720 primarily affected circulating T cells, in particular CD4 T cells, in the 
blood (Fig. 4b).
Effects of FTY720 on the cytokine production potential in MAITs, CD8 T cells, and in CD4 T 
cells
Given that FTY720 treatment altered the cytokine production profile in CD4 T cells 
(Song et al. 2014), the potential to produce IFNγ, TNFα, and IL-17A from MAITs, CD8, 
and CD4 T cells was assessed (Fig. 5). Besides these cytokines, the production of GM-
CSF was also measured, because GM-CSF is a hallmark of MAITs and has been sug-
gested to be pathogenic in MS (Croxford et al. 2015; Cui et al. 2015; Rahimpour et al. 
2015; Wakao et al. 2013) (Additional file 7: Figure S5). SPICE analysis has revealed a dif-
ference in the cytokine production profile in CD4 T cells between and HD and FTY720-
treated groups, and between untreated and FTY720-treated groups (Fig. 5a). However, 
no or little difference was observed in MAITs and CD8 T cells (Fig. 5a). When two way 
ANOVA was performed for all the possible pairs among HD, untreated, and FTY720-
treated groups in terms of cytokine production profile, we observed a decline in the 
relative frequency of cells producing both IFNγ and TNFα in MAITs from untreated 
group relative to that in HD (Fig.  5b). Intriguingly, FTY720 treatment enhanced the 
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M
FI
Fig. 3 Effects of FTY720 on the cell surface antigen expression in MAITs. The mean fluorescence intensity 
(MFI) for the indicated cell surface antigens in DN MAITs and in CD8hi MAITs from untreated subjects (n = 15), 
and subjects treated with FTY720 for 3 months (n = 5), 1 year (n = 6), and 2 years (n = 5), are plotted. 3 m, 
1 y, and 2 y; subjects treated with FTY720 for 3 months, 1 and 2 years, respectively. Data are analyzed with 
Kruskal–Wallis test with Dunn’s multiple comparison test for all the possible combinations. Groups showing 
a statistical significance are indicated with asterisk (*P < 0.05). Data are presented as horizontal lines: median; 
boxes: 25th percentile and 75th percentile; whiskers: minimum and maximum
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in untreated group. Similarly, CD4 T cells harbored more double producer cells upon 
FTY720 treatment than those in HD (Fig. 5b). In marked contrast, FTY720 treatment 
decreased the relative frequency of TNFα single producer cells from CD4 T cells com-
pared with that in HD and in untreated groups (Fig. 5b). Similarly, the same regimen 
resulted in a decline in the frequency of IFNγ single producer cells from CD8 T cells 
(Fig. 5b). Although the number of the subjects was quite limited (n = 4, per group), the 
cytokine production test revealed the effects of the disease and of FTY720 on MAITs, 
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Fig. 4 Effects of FTY720 on lymphocytes. a Time course of lymphocytes counts during FTY720 treatment. 
The lymphocyte counts in the each individual (#2, 3, 4, 6, and 8) were followed from the pre-drug to 3 years 
and half with a mean interval of 3 months. b Effect of FTY720 on blood cells. The absolute counts of the 
indicated subsets in the blood from HDs (n = 9) and from subjects treated with FTY720 for 3 years (n = 5) are 
shown. P < 0.05 indicates statistical significance (Mann–Whitney U test). All data are presented as horizontal 
lines: median; boxes: 25th percentile and 75th percentile; whiskers: minimum and maximum
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Fig. 5 Cytokine production from the lymphocytes. a Comparison of the cell subsets capable of producing 
the cytokines. The relative percentages of cells being capable of secreting the indicated set of cytokines 
within MAITs, conventional CD8 and CD4 T cells from HDs (n = 4) and untreated (n = 4: UT) and FTY720-
treated (treatment for 1 and 2 years, n = 4: FTY) subjects are shown as a pie chart. An asterisk indicates 
statistical significance after the partial Permutation test *P < 0.05; **P < 0.01). b Frequency of cells producing 
a different set of cytokines. The relative percentage of cells producing the indicated cytokine combination 
from HD (n = 4), untreated (n = 4: UT), and FTY720-treated (treatment for 1 and 2 years, n = 4:FTY) subjects 
is shown. The statistical significances are analyzed by Two-way ANOVA and P values are corrected with Holm-
Sidak test. An asterisk indicates the groups exhibiting a statistical difference (*P < 0.05; ***P < 0.001). All data 
are presented as horizontal lines: median; whiskers: minimum and maximum
Page 12 of 16Sugimoto et al. SpringerPlus  (2016) 5:1259 
Discussion
It has been proposed that MAITs are implicated in the pathophysiology of MS, although 
the phenotype and function of MAITs in MS have not been explored extensively (Illés et al. 
2004; Miyazaki et al. 2011; Willing et al. 2014). Our present finding that FTY720 induced 
depletion of CD8hi MAITs revealed that CD8 MAITs constituted CD8hi and DN cells 
in HDs and in MS. Furthermore, depletion of CD8hi MAITs in untreated- and FTY720-
treated subjects indicated that this phenomenon was specific for MS irrespective of drug 
use, suggesting that the phenotype of MAITs was affected in the disease, and the drugs 
could not restore the original state. Accordingly, the expression of CCR5, an inflamma-
tory chemokine receptor, remained higher in untreated- and FTY720-treated subjects than 
that in HD CD8hi MAITs, indicating that MAITs were activated (Additional file 5: Figure 
S3A). Of note, a higher serum level of CCR5 ligands such as CCL3 and CCL5 has been 
found in MS patients, although the effects of these ligands on the disease has yet to be 
elucidated (Khaiboullina et al. 2015). Similarly, an increase in serum CCL20, a ligand for 
CCR6, has been reported in MS patients (Jafarzadeh et al. 2014). The beneficial effects of 
FTY720 consisted of trapping naive and central memory T and B cells that express CCR7 in 
lymph nodes, thus preventing egress of the pathogenic cells from recirculation (Brinkmann 
2009). A significant decrease in CD4 and CD8 T cells, as well as MAITs, upon FTY720 
administration, as shown in Fig. 4, suggested that CCR7+ MAITs could be present in MS, 
probably during the acute relapse stage or in the secondary lymphoid organs, which we 
did not examine in this study. Given that MAITs exhibit an effector/memory phenotype 
being CCR7−CD28+CD27+CR45RO+ in healthy individuals, such an aberrant phenotype 
could represent the pathogenic cells (Dusseaux et al. 2011). In line with the hypothesis, an 
increase in the expression of CD45RA in FTY-2y subjects relative to that in HDs, has been 
observed, implying that MAITs have become so-called T effector-memory RA (TEMRA) cells 
(Additional file 6: Figure S4B). Because CD8 TEMRA cells stem from central memory T cells 
(CCR7+CD45RA−) upon homeostatic proliferation independent of a specific antigen stim-
ulus, the origin of CD45RA+ MAITs may be CCR7+ cells as described above, provided that 
the differentiation of MAITs operated similar that of CD8 TEMRA cells (Geginat et al. 2003). 
Although a recent report has indicated that MAITs are largely CCR7− in untreated MS 
patients, CCR7+ MAITs could be present in FTY720-treated patients (Salou et al. 2016). 
Furthermore, the enhanced expression of CD107a concomitant with a decline in CD27 after 
1 year of FTY 720 therapy indicated that DN MAITs had become terminally differentiated 
effector/memory cells, although the data for CD57, a marker of terminal differentiation, 
together with those for perforin, an effector molecule for exerting cytotoxicity, were miss-
ing (Fig. 3) (Brenchley et al. 2003). Nonetheless, of note was that this phenotype seemed to 
be reversed after 2 years of FTY720 treatment, indicating that less mature effector/memory 
MAITs re-accumulate in the blood (Fig. 3). These results reflected the dynamics of MAITs 
in MS and may mirror the status of MAITs during the course of drug regimens.
CCR6 is expressed in Th17 cells, which have been considered to be pathogenic in 
MS (Jadidi-Niaragh and Mirshafiey 2011; Rostami and Ciric 2013). FTY720 traps most 
Th17 cells within lymph nodes, thus preventing further deleterious effects in the CNS. 
Indeed, many Th17 cells are found in lesions in the brain of MS patients (Tzartos et al. 
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2008). Intriguingly, the lesions contained as many IL-17-producing CD8 T cells (Tc17 
cells) as Th17 cells (Tzartos et al. 2008). Given that no or only very few CD8 T produces 
IL-17, and that MAITs are present at lesions, as in the case for Th17 and Tc17 cells, CD8 
MAITs would be deleterious in MS. The fact that FTY720 enhanced the frequency of 
cells producing both TNFα and IFNγ, in MAITs, CD8 T cells, and CD4 T cells, while 
declining that of TNFα single-producer cells in CD4 T cells suggested beneficial effects 
of FTY720 on the host defense against infection (Fig. 5b). GM-CSF from pathogenic Th 
cells has been suggested to play a pivotal role in the pathology of MS by instigating mye-
loid cells to cause CNS damage (Croxford et al. 2015). Our present data, however, did 
not detect any differences in the production of GM-CSF from different subject groups 
irrespective of the cell sources (Fig. 5b). This might be due to the artificial stimulus used 
in the study, and it is conceivable that MAITs from relapsing MS patients could produce 
more GM-CSF. The presence of such pathogenic MAITs has yet to be explored.
Increases in the relative frequency of MAITs upon FTY 720 therapy could be due to 
the loss of naïve and central memory cells from the periphery and suggested that MAITs 
would continue to play a role in host defense against bacterial and/or fungal pathogens 
in highly lymphopenic conditions, regardless of the fact that absolute lymphocyte num-
bers declined sharply (Fig. 4). This hypothesis may be underpinned by a phase 3 trial of 
FTY720, demonstrating that patients receiving FTY720 or placebo had quasi-identical 
incidences of upper respiratory and urinary infections, but the occurrence of viral infec-
tions increased slightly in the former group at up to 2 years (Calabresi et al. 2014). In 
line with this, MAITs do not recognize viral proteins (Dusseaux et al. 2011). A follow-up 
study for more than 3 years should be conducted to see whether MAIT cell number still 
continue to decrease along with FTY 720 therapy, because depletion of MAITs from the 
peripheral blood would make patients susceptible to infection, in particular, to oppor-
tunistic infection as observed in the case of HIV-infected patients with persistently low-
ered MAITs (Leeansyah et al. 2013; Sandberg et al. 2013). The significant drop of MAIT 
cell number could be attributed either to the slow cell death caused by FTY720 or to the 
death caused by the lack of unknown trophic factors for MAITs being stemmed from 
other lymphocytes or cells. Alternatively, MAITs may be susceptible to death caused by 
FTY720-mediated activation. Most importantly, the increase in the relative frequency of 
CD8hi MAITs concomitant with a decline in DN MAITs after 3 years of FTY 720 therapy 
suggest that the co-receptor composition of MAITs has recovered to normal except for 
CD4 MAITs, which had remained low (Fig. 2). Such dynamics of MAITs could reflect to 
those of MS status, although more studies will be warranted in the future.
Conclusions
FTY 720 therapy enhanced the relative frequency of MAITs in MS patients in a time-
dependent manner. Although the expression of CD8 in MAITs has been affected early 
by FTY720, longer treatment has reversed the phenotypic change. These data demon-
strated that FTY720 induced dynamic change in the relative frequency and in the phe-
notype of MAITs in MS.
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**: P < 0.01, ***: P < 0.001). ns; not significant.
Additional file 4: Figure S2. Cell surface antigen expression in MAITs from healthy donors. (A) Cell surface antigens 
exhibiting different levels of expression in DN MAITs and CD8hi MAITs from HDs. (B) Cell surface antigens exhibiting 
little difference in expression in DN MAITs and CD8hi MAITs from HDs. (A and B) MFI for the indicated cell surface 
antigens in DN MAITs and CD8hi MAITs from HDs (n = 16) is shown. Asterisks indicate a statistically significant differ-
ence (*: P < 0.05, **: P < 0.01, ***: P < 0.001, Mann–Whitney U test). (C) Cell surface antigens exhibiting different levels 
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lis test with Dunn’s multiple comparison test for all the possible combinations. Groups showing a difference are 
indicated with an asterisk (*: P < 0.05, **: P < 0.01, ***: P < 0.001, ****:P < 0.0001). All data are presented as horizontal 
lines: median; boxes: 25th percentile and 75th percentile; whiskers: minimum and maximum.
Additional file 5: Figure S3. Cell surface antigen expression in MAITs in the disease. a Comparative analysis of the 
cell surface antigen expression in MAITs between HDs and untreated subjects. The MFI for the indicated cell surface 
antigens in DN MAITs and in CD8hi MAITs from HDs (n = 16) and untreated subjects (n = 15, UT) are plotted. (B) 
Comparative analysis of cell surface antigen expression in MAITs between untreated and IFNβ-treated subjects. The 
MFI for the indicated cell surface antigens in DN MAITs and CD8hi MAITs from untreated (n = 15: UT) and IFNβ-
treated (n = 14) subjects are plotted. (A and B) P < 0.05 indicates a statistical significance (Mann–Whitney U-test). 
Data are presented as horizontal lines: median; boxes: 25th percentile and 75th percentile; whiskers: minimum and 
maximum.
Additional file 6: Figure S4. Effects of FTY720 on expression of the cell surface antigens in MAITs. (A) The MFI for 
the indicated cell surface antigens in DN MAITs and in CD8hi MAITs from untreated (n = 15, UT) subjects and from 
FTY720-treated patients for 3 months (n = 5, 3 m), 1 year (n = 6, 1 y), and 2 years (n = 5, 2 y) are plotted. Data are 
analyzed with Kruskal–Wallis test with Dunn’s multiple comparison test for all the possible combinations. (B) Effects 
of FTY720 on CD45RO and CD45RA MFI for CD45RO and CD45RA in DN MAITs and CD8hi MAITs from HDs (n = 16) 
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Additional file 7: Figure S5. Gating strategy of intracellular cytokine staining. Left panels: Gating for MAIT cells, 
CD4 T cells and CD8 T cells is depicted. Production of the indicated cytokines from these cells is measured after per-
meabilization. The numbers in the figure represent the percentage of the cell populations producing the indicated 
cytokines. Isotype control staining is also shown for each subset. Representative data are shown.
Page 15 of 16Sugimoto et al. SpringerPlus  (2016) 5:1259 
Pharmacology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. 6 Sapporo Neurology Hospital, Sap-
poro, Japan. 
Acknowledgements
We thank Tomoko Furukawa and Tomomi Matsunaga for excellent technical support.
Competing interests
The authors declare that they have no conflict of interest. KY and UK are employees of Asubio Pharma.
Ethics approval and consent to participate
Sample collection and informed consent procedures were approved by Hokkaido University Hospital Ethical Committee 
for this study (Approval Number: ji 011-0104) and patient written informed consent were obtained before study partici-
pation in accordance with the Declaration of Helsinki.
Funding
The work was supported, in part, by Japan Society for the Promotion of Science [Grants-in Aid for Scientific Research (B) 
22390119 and Scientific Research (C) 26430084].
Received: 22 May 2016   Accepted: 27 July 2016
References
Annibali V, Ristori G, Angelini DF, Serafini B, Mechelli R, Cannoni S, Romano S, Paolillo A, Abderrahim H, Diamantini A, 
Borsellino G, Aloisi F, Battistini L, Salvetti M (2011) CD161(high)CD8+ T cells bear pathogenetic potential in multiple 
sclerosis. Brain 134:542–554. doi:10.1093/brain/awq354
Birkinshaw RW, Kjer-Nielsen L, Eckle SBG, McCluskey J, Rossjohn J (2014) MAITs, MR1 and vitamin B metabolites. Curr Opin 
Immunol 26:7–13. doi:10.1016/j.coi.2013.09.007
Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, Casazza JP, Kuruppu J, Migueles SA, Connors M, 
Roederer M, Douek DC, Koup RA (2003) Expression of CD57 defines replicative senescence and antigen-induced 
apoptotic death of CD8+ T cells. Blood 101:2711–2720. doi:10.1182/blood-2002-07-2103
Brinkmann V (2009) FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous 
system. Br J Pharmacol 158:1173–1182. doi:10.1111/j.1476-5381.2009.00451.x
Calabresi PA, Radue E-W, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, 
Cappiello L, von Rosenstiel P, Lublin FD (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting 
multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 
13:545–556. doi:10.1016/S1474-4422(14)70049-3
Cho Y-N, Kee S-J, Kim T-J, Jin HM, Kim M-J, Jung H-J, Park K-J, Lee S-J, Lee S-S, Kwon Y-S, Kee HJ, Kim N, Park Y-W (2014) 
Mucosal-associated invariant T cell deficiency in systemic lupus erythematosus. J Immunol 193:3891–3901. 
doi:10.4049/jimmunol.1302701
Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502–1517. doi:10.1016/S0140-6736(08)61620-7
Confavreux C, Vukusic S (2006) Age at disability milestones in multiple sclerosis. Brain 129:595–605. doi:10.1093/brain/
awh714
Croxford AL, Spath S, Becher B (2015) GM-CSF in neuroinflammation: licensing myeloid cells for tissue damage. Trends 
Immunol 36:651–662. doi:10.1016/j.it.2015.08.004
Cui Y, Franciszkiewicz K, Mburu YK, Mondot S, Le Bourhis L, Premel V, Martin E, Kachaner A, Duban L, Ingersoll MA, Rabot 
S, Jaubert J, De Villartay J-P, Soudais C, Lantz O (2015) Mucosal-associated invariant T cell-rich congenic mouse strain 
allows functional evaluation. J Clin Invest 125:4171–4185. doi:10.1172/JCI82424
Dusseaux M, Martin E, Serriari N, Péguillet I, Premel V, Louis D, Milder M, Le Bourhis L, Soudais C, Treiner E, Lantz O (2011) 
Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 117:1250–1259. 
doi:10.1182/blood-2010-08-303339
Geginat J, Lanzavecchia A, Sallusto F (2003) Proliferation and differentiation potential of human CD8 + memory T-cell 
subsets in response to antigen or homeostatic cytokines. Blood 101:4260–4266. doi:10.1182/blood-2002-11-3577
Huseby ES, Huseby PG, Shah S, Smith R, Stadinski BD (2012) Pathogenic CD8 T cells in multiple sclerosis and its experi-
mental models. Front Immunol 3:64. doi:10.3389/fimmu.2012.00064
Illés Z, Shimamura M, Newcombe J, Oka N, Yamamura T (2004) Accumulation of Valpha7.2-Jalpha33 invariant T cells in 
human autoimmune inflammatory lesions in the nervous system. Int Immunol 16:223–230
Jadidi-Niaragh F, Mirshafiey A (2011) Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J 
Immunol 74:1–13. doi:10.1111/j.1365-3083.2011.02536.x
Jafarzadeh A, Bagherzadeh S, Ebrahimi HA, Hajghani H, Bazrafshani MR, Khosravimashizi A, Nemati M, Gadari F, Sabahi A, 
Iranmanesh F, Mohammadi MM, Daneshvar H (2014) Higher circulating levels of chemokine CCL20 in patients with 
multiple sclerosis: evaluation of the influences of chemokine gene polymorphism, gender, treatment and disease 
pattern. J Mol Neurosci 53:500–505. doi:10.1007/s12031-013-0214-2
Khaiboullina SF, Gumerova AR, Khafizova IF, Martynova EV, Lombardi VC, Bellusci S, Rizvanov AA (2015) CCL27: 
novel cytokine with potential role in pathogenesis of multiple sclerosis. Biomed Res Int 2015:189638. 
doi:10.1155/2015/189638
Le Bourhis L, Guerri L, Dusseaux M, Martin E, Soudais C, Lantz O (2011) Mucosal-associated invariant T cells: unconven-
tional development and function. Trends Immunol 32:212–218. doi:10.1016/j.it.2011.02.005
Page 16 of 16Sugimoto et al. SpringerPlus  (2016) 5:1259 
Leeansyah E, Ganesh A, Quigley MF, Sönnerborg A, Andersson J, Hunt PW, Somsouk M, Deeks SG, Martin JN, Moll M, 
Shacklett BL, Sandberg JK (2013) Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted 
MAIT-cell population in chronic HIV-1 infection. Blood 121:1124–1135. doi:10.1182/blood-2012-07-445429
Lim SY, Constantinescu CS (2010) Current and future disease-modifying therapies in multiple sclerosis. Int J Clin Pract 
64:637–650. doi:10.1111/j.1742-1241.2009.02261.x
Miyazaki Y, Miyake S, Chiba A, Lantz O, Yamamura T (2011) Mucosal-associated invariant T cells regulate Th1 response in 
multiple sclerosis. Int Immunol 23:529–535. doi:10.1093/intimm/dxr047
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, 
Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky 
JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302. 
doi:10.1002/ana.22366
Pröbstel A-K, Sanderson NSR, Derfuss T (2015) B cells and autoantibodies in multiple sclerosis. Int J Mol Sci 16:16576–
16592. doi:10.3390/ijms160716576
Rahimpour A, Koay HF, Enders A, Clanchy R, Eckle SBG, Meehan B, Chen Z, Whittle B, Liu L, Fairlie DP, Goodnow CC, 
McCluskey J, Rossjohn J, Uldrich AP, Pellicci DG, Godfrey DI (2015) Identification of phenotypically and function-
ally heterogeneous mouse mucosal-associated invariant T cells using MR1 tetramers. J Exp Med 212:1095–1108. 
doi:10.1084/jem.20142110
Roederer M, Nozzi JL, Nason MC (2011) SPICE: exploration and analysis of post-cytometric complex multivariate datasets. 
Cytometry A 79:167–174. doi:10.1002/cyto.a.21015
Rostami A, Ciric B (2013) Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J Neurol Sci 
333:76–87. doi:10.1016/j.jns.2013.03.002
Salou M, Nicol B, Garcia A, Baron D, Michel L, Elong-Ngono A, Hulin P, Nedellec S, Jacq-Foucher M, Le Frère F, Jousset 
N, Bourreille A, Wiertlewski S, Soulillou JP, Brouard S, Nicot AB, Degauque N, Laplaud DA (2016) Neuropathologic, 
phenotypic and functional analyses of Mucosal Associated Invariant T cells in Multiple Sclerosis. Clin Immunol 
166–167:1–11. doi:10.1016/j.clim.2016.03.014
Sandberg JK, Dias J, Shacklett BL, Leeansyah E (2013) Will loss of your MAITs weaken your HAART? AIDS 27:2501–2504. 
doi:10.1097/QAD.0b013e3283620726
Serriari N-E, Eoche M, Lamotte L, Lion J, Fumery M, Marcelo P, Chatelain D, Barre A, Nguyen-Khac E, Lantz O, Dupas J-L, 
Treiner E (2014) Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. 
Clin Exp Immunol 176:266–274. doi:10.1111/cei.12277
Song Z-Y, Yamasaki R, Kawano Y, Sato S, Masaki K, Yoshimura S, Matsuse D, Murai H, Matsushita T, Kira J-I (2014) Periph-
eral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod. PLoS ONE 10:e0124923. 
doi:10.1371/journal.pone.0124923
Sugimoto C, Konno T, Wakao R, Fujita H, Fujita H, Wakao H (2015) Mucosal-associated invariant T cell is a potential marker 
to distinguish fibromyalgia syndrome from arthritis. PLoS ONE 10:e0121124. doi:10.1371/journal.pone.0121124
Teunissen MBM, Yeremenko NG, Baeten DLP, Chielie S, Spuls PI, de Rie MA, Lantz O, Res PCM (2014) The IL-17A-producing 
CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T 
cells. J Invest Dermatol 134:2898–2907. doi:10.1038/jid.2014.261
Treiner E, Liblau RS (2015) Mucosal-associated invariant T cells in multiple sclerosis: the Jury is still out. Front Immunol 
6:503. doi:10.3389/fimmu.2015.00503
Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L (2008) Interleukin-17 production in central 
nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 
172:146–155. doi:10.2353/ajpath.2008.070690
Wakao H, Yoshikiyo K, Koshimizu U, Furukawa T, Enomoto K, Matsunaga T, Tanaka T, Yasutomi Y, Yamada T, Minakami 
H, Tanaka J, Oda A, Sasaki T, Wakao R, Lantz O, Udagawa T, Sekiya Y, Higuchi K, Harada N, Nishimura K, Ohtaka M, 
Nakanishi M, Fujita H (2013) Expansion of functional human mucosal-associated invariant T cells via reprogramming 
to pluripotency and redifferentiation. Cell Stem Cell 12:546–558. doi:10.1016/j.stem.2013.03.001
Willing A, Leach OA, Ufer F, Attfield KE, Steinbach K, Kursawe N, Piedavent M, Friese MA (2014) CD8+ MAIT cells infiltrate 
into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis. Eur J 
Immunol 44:3119–3128. doi:10.1002/eji.201344160
